



Novacyt Named in Deloitte Technology Fast 500

Paris, France and Cambridge, UK – 10 December, 2015 – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, has been named in the Deloitte Technology Fast 500 for Europe, Middle East and Africa.

Novacyt was named as one of the 500 fastest growing technology companies in Europe, Middle East and Africa, according to increase in revenue, having seen growth of +412% between 2011 and 2014 due to its merger in UK company Lab21 in 2014. Novacyt was placed 243 out of 500.

The Deloitte Technology Fast 500 is the pre-eminent technology awards programme in Europe, Middle East and Africa and winners combine technological innovation, entrepreneurship and rapid growth. This follows Novacyt having recently been placed in the Deloitte Technology Fast 50 in France.

In addition to a significant growth in revenue, Novacyt continues to develop and expand its novel diagnostic technology and is expanding its global reach into new markets including China and the Middle East. The company has also signed a number of key strategic deals with global partners such as Leica Biosystems.

Graham Mullis, Group CEO of Novacyt, commented:

*"Novacyt has delivered considerable growth since its merger with Lab21 through the investment and synergies of our commercial infrastructure. In France, where we sell the NOVAprep® technology through our own direct sales channel we have also achieved a milestone of supporting **1.5 million cervical cancer tests** since launching the NOVAprep® product. We are therefore delighted to have been named in the Deloitte Technology Fast 500, and look forward to our continued association with such a prestigious award."*

- Ends -



About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAprep® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com



Contacts:

International media and investor enquiries:

Tony Stephenson

Exitus Communications

+44 (0) 7899 796655

tony@exituscommunications.co.uk

French Investor & Media

Emmanuel Huynh

Newcap

+33 (0) 1 44 71 94 95

novacyt@newcap.fr

NOVACYT

Graham Mullis

Chief Executive Officer

+44 (0) 7901 514121

Graham.mullis@novacyt.com